[4] Dennerstein L, Hayes R, Sand M, et al. Attitudes toward and frequency of partner interactions among women reporting decreased sexual desire. J Sex Med. 2009;6:1668-1673
[5] Basson R. Women's sexual dysfunction revised and expanded definitions. CMAJ. 2005;172:1327-1333
[6] Jolly E, Clayton AH, Thorp J, et al. Efficacy of flibanserin 100mg qhs as a potential treatment for Hypoactive Sexual Desire Disorder in North American pre-menopausal women. Abstract accepted to the European Society of Sexual Medicine Congress, November 2009.
[7] Nappi R, Dean J, van Lunsen H, et al. Efficacy of flibanserin as a potential treatment for Hypoactive Sexual Desire Disorder in European pre-menopausal women: Results from the ORCHID trial. Abstract accepted to the European Society of Sexual Medicine Congress, November 2009.
[8] Jolly E, Clayton AH, Thorp J, et al. Safety and tolerability of flibanserin in pre-menopausal women with Hypoactive Sexual Desire Disorder. Abstract accepted to the European Society of Sexual Medicine Congress, November 2009.
Contacts: Dr. Heike Specht, Corporate Division Communications, Boehringer Ingelheim GmbH, 55216 Ingelheim/Germany, Mobile: +49(151)15-02-29-30, Fax: +49(6132)77-6601, spechthe@boehringer-ingelheim.com; Judith von Gordon, Corporate Division Communications, Boehringer Ingelheim GmbH, 55216 Ingelheim/Germany, Mobile: +49(178)2905056, Judith.vonGordon@boehringer-ingelheim.com
